Shanghai Beiwanta Biotechnology

Shanghai Beiwanta Biotechnology is a biopharmaceutical company headquartered in Shanghai, China, specializing in the development of next-generation mRNA therapeutics. Founded in 2021, the company focuses on circular RNA (circRNA) technology, which offers superior stability and longer-lasting protein expression compared to traditional linear mRNA. Beiwanta's proprietary platform is designed to create innovative vaccines and therapies for infectious diseases and oncology. The company's lead programs include a circRNA-based COVID-19 vaccine and candidates for influenza. Supported by prominent investors such as Sequoia China and GL Ventures, Beiwanta is positioned as a leader in the emerging field of circular RNA medicine in Asia.